SUMO4

Across TCGA pan-cancer cohorts, SUMO4 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SUMO4 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher SUMO4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUMO4 expression acts as an unfavorable survival marker.

ESCA are the cancer types where SUMO4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.023	0.533	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

SUMO4–ESCA (DFS)

Open the ESCA breakdown →